Group 1 - The company proposes to increase its authorized share capital from HKD 50 million (split into 1 billion shares) to HKD 100 million (split into 2 billion shares) by adding an additional 1 billion unissued shares, subject to approval at a special general meeting [1] - Following the increase in authorized share capital, the company plans to conduct a rights issue at a subscription price of HKD 0.08 per share, offering 1 share for every share held as of the record date, aiming to issue between 560 million and 641 million shares to raise at least approximately HKD 44.82 million before expenses [1] Group 2 - The estimated net proceeds from the rights issue will be at least approximately HKD 40.82 million and not exceeding approximately HKD 47.28 million, depending on the exercise of outstanding share options [2] - The company intends to use the net proceeds for several purposes, including: (i) developing existing pharmaceutical wholesale and distribution business, as well as dialysis treatment and consulting services, and potential investments in the healthcare sector; (ii) settling trade and other payables of approximately HKD 5 million and repaying a director's loan and accrued interest of approximately HKD 8.5 million; (iii) general working capital, including salaries, rent, professional fees, and other corporate expenses [2]
万嘉集团拟增加法定股本及按“1供1”基准进行供股